Alzheimer's Prevention Trial - A Unique Patient Population

Genentech, the Banner Alzheimer's Institute, and the National Institutes of Health are collaborating on the first-ever prevention trial in cognitively healthy individuals who are likely to develop Alzheimer's disease due to their genetic history. In this video, Richard Schelller, Genentech's Executive Vice President of Research and Early Development, discusses why this particular patient population is so unique and how Alzheimer's has had an impact on their lives.